Catalyst Event

Alnylam Pharmaceuticals Inc (ALNY) · Earnings Release

From KEDI Global Longevity Bio Index (KGLB)

4/30/2026, 12:00:00 AM

Earnings ReleaseSentiment: Neutral

Alnylam is scheduled to report its Q1 2026 financial results before the market opens on April 30, 2026. Analysts forecast EPS of $1.50 and revenue of approximately $1.13 billion. A neutral impact is expected as the market usually anticipates these figures, scheduled.

Korean Translation

2026년 4월 30일 장 개장 전 2026년 1분기 재무 실적 발표 예정임. 분석가들은 주당순이익 1.50달러, 매출 약 11억 3천만 달러로 전망됨. 시장이 이미 전망치를 반영하고 있어 중립적인 영향이 예상됨.

Related Recent Events

View Full Timeline